This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hereditary factor XI deficiency유전성 제11인자결핍 (유전성 제십일인자결핍증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D68.1 (hereditary factor XI deficiency) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsHemophilia C, Rosenthal syndrome, Plasma Thromboplastin Antecedent deficiency (PTA deficiency), hereditary coagulation factor XI deficiency, Hemophilia C, Factor XI deficiency, Congenital factor XI deficiency
C. Adult onsetPossibility of first onset in adulthood: very high — unlike hemophilia A and B, hemophilia C rarely causes spontaneous bleeding and is often not diagnosed in childhood; cases first discovered in adulthood through abnormal bleeding in situations of hemostatic stress such as surgery, tooth extraction, trauma, or delivery account for the majority of all patients; because blood FXI activity and bleeding tendency are not always proportional, some patients remain asymptomatic for life even with very low FXI:C.
1. HistoryFirst described in 1953 by Rosenthal et al. in Ashkenazi Jewish families. Named PTA deficiency, later also called 'hemophilia C'.
2. CausesPathogenic variants in the F11 gene located on the long arm of chromosome 4 at 4q35.2; autosomal recessive inheritance; heterozygote frequency about 8% in Ashkenazi Jews due to a founder effect.
3. GeneticsF11 gene 4q35.2, 23 kb, 15 exons, mature protein 625 amino acids (80 kDa homodimer). Main Ashkenazi Jewish founder variants: Glu117Ter (E117X), Phe283Leu (F283L). Autosomal recessive inheritance.
4. EpidemiologyGeneral population prevalence about 1/1 million (severe); among Ashkenazi Jews, homozygous or compound heterozygous about 1/450, heterozygous about 8%. Rarely reported in Korea.
5. PathophysiologyFXI deficiency → decreased contact activation of the intrinsic coagulation pathway → persistent insufficiency of thrombin generation within the clot → vulnerable secondary hemostasis, especially at sites of high fibrinolytic activity (oral and genitourinary mucosa).
6. SymptomsSpontaneous bleeding rare; excessive bleeding after surgery, tooth extraction, or trauma is the main symptom; mucosal bleeding of the mouth, nose, and genitourinary tract common; menorrhagia and postpartum hemorrhage in women; correlation between FXI:C and bleeding severity unclear.
7. SignsIsolated APTT prolongation, decreased FXI:C, normal PT, platelets, and bleeding time. Mild APTT prolongation possible even in severe (FXI:C <20%) heterozygotes. Inhibitor formation rare, but reported after massive FFP treatment.
8. ScreeningDetection of APTT prolongation before surgery, family history investigation, identification of Ashkenazi Jewish background, F11 gene panel testing. Caution with automated APTT prolongation thresholds (even mild prolongation may be clinically significant).
9. DiagnosisConfirm APTT prolongation → FXI:C one-stage assay → mixing test → differentiation from other contact factors (FXII, prekallikrein, HMW kininogen) → F11 gene analysis (Sanger/NGS).
10. TreatmentFresh frozen plasma (FFP), FXI concentrate (approved in Europe), antifibrinolytics (tranexamic acid), limited effect of DDAVP; with inhibitor development, recombinant FVIIa or activated prothrombin complex concentrate.
11. PrognosisNormal life expectancy. Most bleeding complications preventable with appropriate preoperative management. Major complications of hemophilia A and B such as hemarthrosis and muscle hematoma are rare. Management may be difficult if inhibitors develop.
12. PreventionGenetic counseling, prenatal testing (CVS/amniocentesis), family screening; check FXI:C before surgery or tooth extraction and give prophylactic FFP/tranexamic acid; avoid nonsteroidal anti-inflammatory drugs and antiplatelet agents.
13. ReferencesRosenthal RL et al. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med. 1953 … and 11 other papers

1. History

Rosenthal's first report in 1953

Hereditary factor XI deficiency is a bleeding disorder first described in 1953 by Robert L. Rosenthal of the United States and colleagues in patients from Ashkenazi Jewish families. At the time, Rosenthal et al. proved through plasma mixing correction experiments that these patients had a deficiency of a coagulation factor different from the previously known hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency). They named this new coagulation factor Plasma Thromboplastin Antecedent (PTA) and called its deficiency 'PTA deficiency'. This name was used for a while, but as the international Roman numeral nomenclature for coagulation factors was organized, the International Society on Thrombosis and Haemostasis officially designated this factor as coagulation factor XI (Factor XI, FXI) in 1961. Thus the disease came to be called hereditary factor XI deficiency and, informally, hemophilia C. However, because its actual clinical picture is essentially different from hemophilia A and B, many experts avoid using the name 'hemophilia C'.

The founder effect and Ashkenazi Jews

The fact that the patient families first described by Rosenthal had an Ashkenazi Jewish background later became a very important clue in epidemiological research. Molecular genetic studies in the 1990s–2000s confirmed that specific variants of the F11 gene have accumulated at high frequency in the Ashkenazi Jewish (Eastern European Jewish) population due to a founder effect. In particular, the Glu117Ter (E117X) variant and the Phe283Leu (F283L) variant are the two most common founder variants in Ashkenazi Jews, and these two variants alone can explain about 90% or more of FXI deficiency in that population. This discovery led to the inclusion of FXI deficiency gene testing in prenatal genetic screening programs in the Ashkenazi Jewish population.

Research on the contact activation pathway and redefinition of the position of FXI

In the coagulation cascade model established in the 1960s, FXI was positioned as a component of the intrinsic pathway activated by activated factor XII (FXIIa). However, later clinical observations confirmed that patients with factor XII (Hageman factor) deficiency do not show serious bleeding, suggesting that in vivo a feedback loop in which FXI is activated mainly by thrombin on the platelet surface is more important than activation by FXIIa. With the proposal of the cell-based model of hemostasis after the 1990s, the role of FXI was redefined as stabilizing the hemostatic clot through activation of FIX on the platelet surface during the amplification and sustaining phase of initial thrombin generation started by tissue factor-FVIIa. This understanding became an important theoretical basis for rationally explaining the unique clinical picture of FXI deficiency—spontaneous bleeding is rare, but postoperative bleeding occurs at specific sites (mucosal areas with high fibrinolytic activity).

Development of antithrombotic agents targeting FXI

The epidemiological observation that FXI deficiency causes a bleeding tendency while possibly having a protective effect against arterial thrombosis drew attention to FXI as a target for thrombosis treatment. Indeed, several epidemiological studies confirmed a tendency for the risk of venous thromboembolism and ischemic stroke to increase with higher FXI levels. Based on this, since the 2010s numerous FXI/FXIa inhibitors such as abelacimab (anti-FXI monoclonal antibody), osocimab (FXIa inhibitor), asundexian, and milvexian have entered clinical development as new antithrombotic drug candidates. Large randomized clinical trials are under way to verify the potential of these drugs as safe antithrombotic agents with lower bleeding risk than existing anticoagulants, and this is cited as a representative case in which molecular genetic research on FXI deficiency led to the development of new therapies.


2. Causes

F11 gene variants

Hereditary factor XI deficiency is caused by pathogenic variants in the F11 gene located on the long arm of chromosome 4 at 4q35.2. The F11 gene has a total length of about 23 kb, consists of 15 exons, and encodes a protein precursor of 625 amino acids. The mature protein FXI exists in plasma as a homodimer, with a molecular weight of about 80 kDa (monomer). To date, hundreds or more pathogenic variants identified in the F11 gene have been registered in coagulation variant databases including the HAMSTeRS database, encompassing various types such as missense variants, nonsense variants, small deletions/insertions, and splicing variants.

Autosomal recessive inheritance: the decisive difference from hemophilia A and B

Hereditary factor XI deficiency is fundamentally different from the X-linked recessive hemophilias A and B in that it follows an autosomal recessive mode of inheritance. Because it is autosomal recessive, it occurs in both sexes, and women are affected at the same rate as men. To manifest the disease, a variant allele must be inherited from each parent, and FXI:C is markedly decreased in the homozygous or compound heterozygous state. Heterozygous carriers may have mildly decreased FXI:C at about 40–60% of normal, and some experience a mild increase in bleeding after surgery or tooth extraction. This contrasts with carriers of X-linked recessive hemophilia, most of whom maintain normal FXI:C.

Ashkenazi Jewish founder variants

The reason hereditary factor XI deficiency, a rare disease worldwide, occurs with uniquely high frequency in the Ashkenazi Jewish population is explained by the founder effect. As a result of a small number of individuals carrying F11 variants among the ancestors of the European Jewish population several hundred years ago spreading the variants within a closed population, the heterozygous carrier frequency in Ashkenazi Jews today is estimated at about 8%, and the frequency of homozygosity or compound heterozygosity (severe deficiency) at about 1/450. The two most common variants in this population are as follows. The type II variant Glu117Ter (E117X, c.349G>T) is a nonsense variant located in exon 5 that causes premature termination of protein synthesis, resulting in a severe decrease in FXI protein amount and activity. The type III variant Phe283Leu (F283L, c.849C>A or c.849C>G) is a missense variant located in exon 9 that interferes with FXI dimer formation, reducing the amount of protein secreted, though the activatable FXI molecule itself may retain some function.

Classification of FXI deficiency types

Hereditary factor XI deficiency is broadly classified into two types according to the antigen level and functional activity level of the FXI protein. Type I (cross-reacting material negative, CRM−) is when both FXI activity (FXI:C) and antigen (FXI:Ag) are decreased, a state in which protein production itself is reduced. This type is mainly caused by nonsense variants, large deletions, or variants impairing dimer assembly (e.g., F283L). Type II (cross-reacting material positive, CRM+) is when FXI antigen is normal or nearly normal but functional activity is decreased; structurally the FXI molecule is produced, but catalytic function is reduced due to variants in the active site or substrate-binding site. Variants found in many non-Ashkenazi patients in Korea and abroad may belong to either type I or type II, and the types of variants are very diverse. The correlation between phenotype and genotype is quite complex, and bleeding tendency can vary considerably even among patients with the same variant.


3. Genetics

F11 gene structure and protein

The F11 gene is located on the long arm of chromosome 4 at 4q35.2, spans about 23 kb of genomic sequence, and contains 15 exons. The precursor including the signal peptide consists of 625 amino acids, and after removal of the 18-amino-acid signal peptide, a mature protein of 607 amino acids is secreted into plasma. A feature distinguishing it from other coagulation factors is that the mature FXI protein exists in plasma as a homodimer linked by a disulfide bond. Because each monomer has a molecular weight of about 80 kDa, the dimer molecular weight in plasma reaches about 160 kDa. The normal plasma FXI concentration is about 4–6 μg/mL (about 30–35 nM).

Protein domain structure: apple domains

Structurally, FXI consists of four unique apple domains (A1–A4) and a C-terminal serine protease catalytic domain. Each apple domain consists of about 90–91 amino acids and maintains a stable structure through internal disulfide bonds. Functionally, the A1 domain contains the Cys321 residue essential for homodimer formation, and the A2 domain contains the binding site for high-molecular-weight kininogen (HMW kininogen). The A3 domain contains the cleavage site (Arg369-Ile370) for thrombin and FXIIa and is directly involved in FXI activation. The A4 domain contains the site that binds platelet glycoprotein Ib (GPIb), allowing FXI to be captured on the activated platelet surface and activated. The serine protease domain contains the catalytic triad (His413, Asp462, Ser557) and performs the main function of cleaving FIX as substrate to generate FIXa.

Main Ashkenazi Jewish variants and their molecular effects

The two most frequent founder variants in Ashkenazi Jews, analyzed at the molecular level, are as follows. E117X (Glu117Ter) is a nonsense variant located in exon 5 that introduces a premature stop codon within the A1 domain. The truncated mRNA produced becomes a target of nonsense-mediated mRNA decay (NMD), so in practice almost no protein is synthesized from this variant allele. Therefore, patients homozygous for this variant show complete deficiency, with both FXI protein and activity nearly zero. F283L (Phe283Leu) is a missense variant located in exon 9 in which Phe283, located in the hydrophobic core of the A4 domain, is replaced by Leu283. This substitution alters the conformation of the A4 domain and interferes with formation of the disulfide bond (Cys321-Cys321') at the monomer-monomer interface, greatly reducing dimer assembly efficiency. As a result, the FXI protein is produced, but dimer formation is poor, so the amount secreted into plasma decreases, and some of the secreted protein exists in monomeric form with low activity. This appears as a typical type I (CRM−) deficiency pattern.

Variant diversity in non-Ashkenazi patients

In hereditary factor XI deficiency occurring in populations other than Ashkenazi Jews, much more diverse F11 variants are reported. The variants reported in various countries including the UK, France, Italy, Japan, and Korea are mostly rare variants found only in individual families, and no standardized founder variants have been identified. This diversity is a factor making diagnosis more difficult in non-Ashkenazi populations. Next-generation sequencing (NGS) or Sanger direct sequencing targeting all exons and intron-exon boundaries of the F11 gene is used as the confirmatory tool. In addition, one study (Bolton-Maggs et al.) emphasized that the bleeding risk due to FXI variants is not sufficiently predicted simply by genotype or FXI:C level, and that the clinical bleeding history with surgery and trauma is the most important factor in treatment decisions.


4. General epidemiology

Worldwide prevalence

Hereditary factor XI deficiency is a rare bleeding disorder much less common than hemophilia A and B, and the prevalence of severe deficiency (FXI:C <20%) in the general population is estimated at about 1/1 million. However, because the clinical symptoms of the disease are mild or nonspecific and diagnosis is often missed, the actual prevalence is likely to be higher than this. Including mild deficiency (FXI:C 20–70%), the prevalence rises to about 1/100,000 or more. The number of registered FXI deficiency patients reported in the 2023 global survey of the World Federation of Hemophilia (WFH) is about 35,000, but the actual number of patients is estimated to greatly exceed this.

Special prevalence in Ashkenazi Jews

The Ashkenazi Jewish population is the ethnic group with the highest prevalence of hereditary factor XI deficiency in the world. In this population, the heterozygous carrier frequency is about 8% (about 1 in 12.5), and the prevalence of severe deficiency due to homozygosity or compound heterozygosity is estimated at about 1/450. In large blood centers in Israel, the United States, Canada, and elsewhere, patients of Ashkenazi Jewish background make up a very high proportion. Because a considerable number of patients reported worldwide come from this population, it should be noted in interpretation that much of the clinical research data on hereditary factor XI deficiency is based on Ashkenazi Jewish cohorts.

Sex distribution and status in Korea

Because hereditary factor XI deficiency is autosomal recessive, it shows equal prevalence in men and women. This is an epidemiological characteristic fundamentally different from the X-linked hemophilias A and B, which have an overwhelmingly higher incidence in males. Mild FXI:C decreases are also observed in heterozygous carrier women, and symptoms such as menorrhagia and postpartum hemorrhage can occur, so clinical attention to female carriers is also needed. In Korea, far fewer patients are registered than for hemophilia A and B, but with the recent spread of NGS-based genetic analysis, F11 variants are increasingly being identified in cases of atypical APTT prolongation. Accurate domestic prevalence data have not yet been systematically collected, and expansion of registry programs is needed in the future.

Co-occurrence with other coagulation disorders

Hereditary factor XI deficiency is not uncommonly reported to co-occur with von Willebrand disease (vWD). This is related to the mechanism by which vWF is indirectly involved in the platelet surface binding and activation of FXI, and when both diseases are present together, the bleeding tendency may be more pronounced than when each is present alone. Cases of FXI deficiency combined with other platelet function disorders such as Glanzmann thrombasthenia have also been reported. These combined deficiency states further emphasize the importance of detailed preoperative assessment of coagulation function.


5. Pathophysiology

The role of FXI in the contact activation pathway

In the classic cascade model of the coagulation system, FXI is a component of the intrinsic pathway (contact activation pathway). When blood comes into contact with negatively charged foreign material (glass, collagen, extracellular matrix, etc.), a contact activation complex forms, factor XII (Hageman factor, FXII) is activated to FXIIa, and a chain reaction begins in which FXIIa activates PK (prekallikrein) to kallikrein. Ultimately, FXIa activates FIX to FIXa, and FIXa forms the intrinsic tenase complex with FVIIIa, activating FX to FXa and leading to thrombin generation. However, it has been confirmed that in vivo, patients with FXII deficiency have no bleeding tendency, suggesting that the main pathway of FXI activation in the body is a mechanism other than FXIIa.

The position of FXI in the cell-based model of hemostasis

In the currently accepted cell-based model of hemostasis, the main activation mechanism of FXI is feedback activation by thrombin. When vascular injury occurs, the tissue factor (TF)-FVIIa complex generates a small amount of initial thrombin. This initial thrombin activates platelets and at the same time directly cleaves FXI bound to the platelet surface, activating it to FXIa. Activated FXIa promotes additional FIX → FIXa conversion on the platelet surface, amplifying the intrinsic tenase and thereby inducing a large thrombin burst. This large amount of thrombin converts fibrinogen to fibrin to form a solid fibrin clot, and at the same time activates TAFI (Thrombin-Activatable Fibrinolysis Inhibitor), suppressing fibrinolysis and thereby stabilizing the hemostatic clot.

FXI deficiency and the special nature of bleeding-prone sites

The reason deep tissue bleeding such as in joints and muscles is rare in FXI deficiency patients is that thrombin generation by the initial tissue factor pathway is relatively maintained. In contrast, at sites with high fibrinolytic activity such as the oral mucosa, nasal cavity, genitourinary tract, and endometrium, insufficient thrombin feedback amplification weakens the thrombin-TAFI feedback, so the formed fibrin clot dissolves prematurely and hemostatic failure occurs. This is the mechanistic basis for why delayed bleeding after procedures, bleeding after tooth extraction, hematuria after urological surgery, menorrhagia, and postpartum hemorrhage are more prominent than traumatic bleeding in FXI deficiency patients. In addition, tonsillectomy is known to be a particularly dangerous procedure in FXI deficiency patients because of the high fibrinolytic activity of the oropharyngeal mucosa.

Discordance between FXI:C level and bleeding phenotype

One of the most distinctive clinicopathological features of hereditary factor XI deficiency is that the correlation between plasma FXI activity (FXI:C) and bleeding phenotype is much less clear than in hemophilia A and B. Patients homozygous for the E117X variant with FXI:C of nearly 0 may remain asymptomatic, and conversely, serious bleeding may occur even in heterozygous carriers with FXI:C of only 20–40%. Mechanistic explanations proposed for this discordance include differences in platelet FXI content, individual differences in fibrinolytic system activity, and differences in the compensatory activity levels of other coagulation factors. Clinically, because of this discordance, it is difficult to accurately predict preoperative bleeding risk from the FXI:C value alone, and treatment strategies must be established by comprehensively considering the patient's past bleeding history, the level of fibrinolytic activity at the surgical site, and the scale of surgery.


6. Symptoms

Rarity of spontaneous bleeding

The clinical feature that most clearly distinguishes hereditary factor XI deficiency from hemophilia A and B is that spontaneous bleeding is very rare. In severe hemophilia A and B, spontaneous joint bleeding (hemarthrosis) and muscle hematomas occur very frequently and lead to repeated joint destruction, but even in severe FXI deficiency (FXI:C <20%), such spontaneous deep tissue bleeding is extremely rare. Most patients lead normal daily lives at ordinary times without particular hemostatic stress (surgery, tooth extraction, trauma, delivery). Because of this feature, the disease is often not diagnosed until adulthood, and some patients go for decades without knowing they have FXI deficiency until the disease is first discovered through abnormal bleeding after a particular procedure.

Bleeding after surgery and procedures

The most common and clinically important bleeding situation in FXI deficiency patients is after surgery or invasive procedures. The bleeding risk is particularly high with the following procedures. Tooth extraction and oral procedures: because of the high fibrinolytic activity of the oral mucosa, delayed bleeding after tooth extraction is very common, and hemostasis is often not achieved with ordinary pressure alone, sometimes requiring transfusion or re-treatment. Tonsillectomy: particularly dangerous because of the rich tissue plasminogen activator (tPA) environment of the pharyngeal mucosa. Urological surgery: the kidney, bladder, and urethral mucosa have high urokinase activity, so urinary tract bleeding readily occurs. Gynecological surgery and delivery: because of the high fibrinolytic activity of the endometrium, bleeding after uterine surgery and postpartum hemorrhage are increased in women with FXI deficiency.

Female-specific symptoms

Because FXI deficiency is an autosomal disease, it occurs in female patients as equally as in males, and women have additional specific symptoms. Menorrhagia is reported in about 50–75% of women with FXI deficiency, and in some, excessive bleeding occurs to the extent of causing severe anemia. The risk of postpartum hemorrhage is increased in women with FXI deficiency, and it can be difficult to predict, especially in combination with the physiological change in which FXI:C rises compensatorily during pregnancy and then drops sharply after delivery. In addition, abnormal bleeding after delivery can occur even in women who are originally heterozygous carriers with borderline FXI:C, so women with FXI deficiency planning to give birth must receive multidisciplinary consultation with a hematologist and obstetrician before delivery.

Special features of bleeding severity classification

Traditionally, FXI:C <20% is classified as severe and 20–70% as mild/moderate, but as described above, this classification does not exactly match the clinical bleeding phenotype. Therefore, many experts emphasize that the patient's actual bleeding history, rather than the FXI:C value, is the most important factor in treatment decisions. If serious bleeding has been experienced in the past with tooth extraction, surgery, or trauma, serious bleeding is likely to occur with subsequent procedures of equal or greater scale. In contrast, patients who have gone through similar stress situations in the past without abnormal bleeding may have a relatively low bleeding risk in the future. It is recommended to systematically record and evaluate bleeding history using a standardized bleeding score (Bleeding Assessment Tool, BAT) system.


7. Signs

Basic coagulation test findings

The most characteristic laboratory finding in hereditary factor XI deficiency is isolated prolongation of the activated partial thromboplastin time (APTT). In severe deficiency (FXI:C <20%), APTT shows a marked abnormality, prolonged by 10–30 seconds or more over the control, and in heterozygous carriers (FXI:C about 40–60%), APTT may be mildly prolonged or lie at the upper end of the normal range. In contrast, the prothrombin time (PT) is normal, and the thrombin time (TT) is also normal. Fibrinogen level and platelet count are not affected by FXI deficiency itself. The bleeding time (BT) is also normal, reflecting that FXI deficiency does not affect primary hemostasis (platelet plug formation).

FXI activity measurement findings

When APTT prolongation is confirmed, FXI:C (factor XI functional activity) is measured by single factor assay. The standard for this test is the one-stage clotting assay using FXI-deficient substrate plasma. The general criteria are severe deficiency: FXI:C <20 IU/dL, heterozygous: 20–70 IU/dL, normal: 70–150 IU/dL. Simultaneous measurement of FXI antigen (FXI:Ag) by immunoassay (ELISA or rocket electrophoresis) allows type I (CRM−, both FXI:C and FXI:Ag decreased) and type II (CRM+, normal FXI:Ag but decreased FXI:C) to be distinguished. In a mixing test, if APTT is corrected when normal plasma and patient plasma are mixed 1:1, factor deficiency is suggested, and if not corrected, an inhibitor should be suspected.

Findings differentiating other contact factor deficiencies

The differential diagnosis of isolated APTT prolongation includes, in addition to FXI deficiency, factor XII (FXII) deficiency, prekallikrein (PK) deficiency, and high-molecular-weight kininogen (HMW kininogen) deficiency. Unlike FXI deficiency, these three contact factor deficiencies do not cause clinical bleeding, so it is important to accurately differentiate them from FXI deficiency. Laboratory points of differentiation require remeasurement of APTT after prolonged activation time (in FXII and PK deficiency, APTT tends to shorten with prolonged time) and single factor assay for each factor. In patients with isolated FXI deficiency alone, FXII:C, PK:C, and HMW kininogen:Ag are all normal. FVIII deficiency (hemophilia A) also shows isolated APTT prolongation, so it must be differentiated by FVIII:C measurement.

Inhibitor development

Development of inhibitors (anti-FXI alloantibodies) in FXI deficiency patients is much rarer than in hemophilia A (about 30%), but cases occurring after massive plasma transfusion or FXI concentrate administration have been reported. When an inhibitor develops, APTT is not corrected in the mixing test. When the inhibitor titer is high, the effect of FFP or FXI concentrates used for FXI deficiency treatment is greatly reduced, and in this case bypassing agents, recombinant activated factor VII (rFVIIa) or activated prothrombin complex concentrate (aPCC), must be used. Some reports have shown a relatively high risk of inhibitor development in E117X homozygous patients, which is presumed to be because these patients have never been exposed to FXI protein and immune tolerance has not been established.


8. Screening

Detection through preoperative APTT testing

Many patients with hereditary factor XI deficiency are first suspected when APTT prolongation is found on routine preoperative coagulation screening. Because spontaneous bleeding is rare in this disease and patients often do not perceive a bleeding tendency themselves, preoperative APTT testing becomes the most important gateway to diagnosis. When APTT prolongation (generally more than 5 seconds above the upper reference limit) is confirmed on screening, the cause must be identified through single factor coagulation assay regardless of whether there is a clinical bleeding history. In particular, unexplained APTT prolongation in patients scheduled for surgery or procedures must be clearly diagnosed before surgery, and surgery should not proceed without the cause being identified.

Screening through family history

Preemptive screening of first-degree relatives of FXI deficiency patients—siblings, parents, children—is recommended. Because it is autosomal recessive, the patient's parents are mostly heterozygous carriers, and heterozygous carriers may also show mild FXI:C decreases and increased risk of postoperative bleeding. The patient's siblings statistically have a 25% probability of being homozygous or compound heterozygous patients, a 50% probability of being heterozygous carriers, and a 25% probability of being normal. Therefore, it is clinically meaningful to measure APTT and FXI:C in the patient's family and, if possible, perform F11 gene analysis to determine carrier status. More active screening is needed especially in family members facing surgical procedures.

Screening in the Ashkenazi Jewish population

In patients with an Ashkenazi Jewish background, the clinical importance of FXI deficiency screening is even greater. Because the heterozygote frequency in this population reaches about 8%, when an Ashkenazi Jewish background is confirmed, it is recommended to include FXI deficiency screening in premarital and preconception genetic counseling. Some medical institutions in Israel operate carrier screening programs for Ashkenazi Jews that include genetic testing for the two founder variants E117X and F283L. The risk of FXI deficiency in Ashkenazi Jews confirmed negative for both variants is very low, providing reassurance without additional testing.

Use of bleeding assessment tools (BAT)

In patients suspected of or diagnosed with FXI deficiency, the use of a standardized Bleeding Assessment Tool (BAT) is recommended to objectively assess clinical bleeding tendency. Representative examples include the ISTH-BAT developed by the International Society on Thrombosis and Haemostasis (ISTH) and the MCMDM-1VWD tool supported by the European Hematology Association (EHA). These tools score severity for each of about 10 bleeding items, such as epistaxis, oral bleeding, bleeding after tooth extraction, postoperative bleeding, menorrhagia, postpartum hemorrhage, gastrointestinal bleeding, and muscle and joint bleeding, to calculate a total bleeding score. An abnormal bleeding score (≥4 in men, ≥6 in women) suggests a clinically significant bleeding tendency and is often more useful than the FXI:C value alone in determining whether treatment is actually needed.


9. Diagnosis

Diagnostic algorithm

Confirmation of hereditary factor XI deficiency is made through stepwise testing. In step 1, coagulation screening tests (PT, APTT, TT, fibrinogen, platelet count) are performed to confirm the pattern of isolated APTT prolongation. In step 2, a mixing test is performed to differentiate whether the cause of APTT prolongation is factor deficiency or an inhibitor. In step 3, single factor assays for the intrinsic pathway factors involved in APTT prolongation (FVIII, FIX, FXI, FXII) and contact factors (prekallikrein, HMW kininogen) are performed sequentially to identify the deficient factor. If FXI:C is decreased, in step 4 FXI:Ag is measured to classify type I (CRM−) and type II (CRM+). In step 5, pathogenic variants are confirmed through F11 gene analysis (Sanger sequencing or next-generation sequencing).

Technical aspects of FXI activity measurement

The standard for FXI:C measurement is the one-stage clotting assay using FXI-deficient substrate plasma. In this test, serial dilutions of patient plasma are mixed with FXI-deficient substrate plasma, APTT is measured, and FXI activity (IU/dL or %) is calculated by comparison with a normal plasma dilution curve. As a precaution, depending on the type of APTT reagent used in some automated coagulation analyzers, mild FXI deficiency may not be sufficiently detected, so it is important to check the sensitivity of the APTT reagent. In addition, FXI:C may be measured low if testing is not performed promptly after blood collection, so standardized blood collection and specimen handling procedures should be followed. Because APTT may be falsely prolonged in the presence of phospholipid-binding antibodies such as lupus anticoagulant (LA), excluding LA through dilute Russell viper venom time (dRVVT) or silica clotting time (SCT) testing is also included in the differential diagnosis.

Role of genetic testing

F11 gene analysis is essential for definitive diagnosis, carrier diagnosis, family screening, and prenatal diagnosis. In the Ashkenazi Jewish population, most patients can be diagnosed with a simple genetic test targeting only the two founder variants E117X (c.349G>T) and F283L (c.849C>A). Because diverse variants are distributed in non-Ashkenazi populations, Sanger direct sequencing covering the entire exon coding region and exon-intron boundaries of the F11 gene, or NGS panel testing targeting a bleeding disorder gene panel (including dozens to hundreds of genes related to platelet abnormalities and coagulation factor deficiencies), is appropriate. Pathogenicity classification of variants is determined according to ACMG guidelines with reference to ClinVar, HGMD (Human Gene Mutation Database), the HAMSTeRS database, and others. The clinical diagnosis can be maintained even when a specific variant is not identified, and in this case additional analysis of deep intronic variants or structural variants (CNV) is considered.

Prenatal and preimplantation genetic diagnosis

FXI deficiency patients or carrier couples can choose prenatal diagnosis or preimplantation genetic testing after fully understanding the risk of their children being affected through genetic counseling. For prenatal diagnosis, the F11 gene of fetal cells is analyzed by chorionic villus sampling (CVS) at 10–12 weeks of pregnancy or amniocentesis at 14–18 weeks of pregnancy. Preimplantation genetic testing (PGT-M) is a method combined with in vitro fertilization (IVF) to check for F11 pathogenic variants at the embryo stage before implantation, and is used selectively when both parents are carriers. However, considering that FXI deficiency mostly does not shorten life expectancy and bleeding can be managed with preventive measures, thorough discussion with the couple about the ethical and clinical significance of prenatal diagnosis and preimplantation testing should come first.


10. Treatment

Basic principles of treatment

Treatment of hereditary factor XI deficiency is based on the principle of an individualized approach based on symptoms and bleeding risk. Patients with no or mild bleeding history do not need treatment in situations without ordinary hemostatic stress, even if their FXI:C value is very low. The main situations requiring treatment are as follows. First, prophylactic treatment before surgery and invasive procedures: for patients with a past bleeding history, or when a procedure is scheduled at a site with high fibrinolytic activity (oral cavity, urinary tract, uterus). Second, treatment of active bleeding: emergency hemostasis when bleeding has already occurred. Third, prevention of bleeding related to pregnancy and delivery: management of peripartum bleeding risk in pregnant women with FXI deficiency. The treatment method is determined by bleeding risk, type of procedure, and available products.

Fresh frozen plasma (FFP)

Fresh Frozen Plasma (FFP) is the traditional treatment for hereditary factor XI deficiency and the most widely available treatment option worldwide. FFP contains all coagulation factors, including FXI. It is usually administered intravenously before and after surgery at a dose of 15–20 mL/kg, aiming to maintain FXI:C at about 70 IU/dL or more. ABO blood group-matched FFP must be used, and because volume overload can occur with large-volume administration, caution is needed in patients with reduced cardiopulmonary function. In addition, because FFP is a plasma-derived product, the risk of infection transmission (although now greatly reduced by leukocyte reduction and pathogen inactivation) is not completely excluded. Despite these drawbacks, FFP becomes the first-line option in settings where no other alternative product is available.

FXI concentrate

Plasma-derived FXI concentrate is available in some European countries (UK, France, Israel, etc.), but it has not been approved by the US Food and Drug Administration (FDA) or the Korean Ministry of Food and Drug Safety, so it is currently not commercially available in Korea. FXI concentrate has the advantage of achieving higher FXI:C at a smaller volume than FFP, with a lower risk of transfusion overload. However, as a precaution in its use, a risk of thrombotic complications has been reported, so the dose must be determined carefully, especially in situations at high risk of postoperative thrombosis (advanced age, cancer surgery, major orthopedic surgery, etc.). In addition, repeated administration of FXI concentrate carries a risk of inhibitor development, and according to UK experience this risk has been reported to be particularly high in E117X homozygous patients.

Antifibrinolytics and DDAVP

Antifibrinolytics, especially tranexamic acid, are very useful adjunctive treatments in FXI deficiency patients. Because of the mechanistic feature that bleeding in FXI deficiency occurs mainly at mucosal sites with high fibrinolytic activity, tranexamic acid is used effectively alone or together with FFP for tooth extraction, minor oral procedures, menorrhagia, urological procedures, and so on. For tooth extraction, using topical administration (mouth rinse) and systemic administration together is effective. Tranexamic acid can be given orally or intravenously, and because of its clinically proven safety and low cost it has become an essential drug in FXI deficiency treatment. DDAVP (desmopressin) sometimes shows some effect in FXI deficiency through vWF release, but unlike in hemophilia A it does not act directly on FXI, so its effect is limited and it is not effective in all patients. It is recommended to confirm the response with a therapeutic trial before minor procedures before using it.


11. Prognosis

Life expectancy and overall prognosis

The life expectancy of patients with hereditary factor XI deficiency under appropriate medical management is the same as that of the normal population. Unlike hemophilia A and B, in which quality of life is greatly reduced by deep tissue bleeding and arthropathy when they progress without prophylaxis, in FXI deficiency spontaneous deep bleeding is rare, so chronic complications such as joint destruction and muscle atrophy do not occur. Accordingly, orthopedic interventions including joint surgery are rarely needed, and there are mostly no restrictions on daily physical activity. Through appropriate advance planning (establishing a treatment plan before surgery and procedures, careful use of antiplatelet agents and nonsteroidal anti-inflammatory drugs, etc.) and self-management education, patients can lead most of their daily lives normally.

Prevention and outcomes of surgery-related bleeding complications

The most important risk factor in the prognosis of FXI deficiency patients is unanticipated abnormal bleeding during surgery and procedures. When tooth extraction, tonsillectomy, hernia surgery, delivery, and so on are performed in patients not diagnosed in advance, serious bleeding complications may occur, which in some cases may be life-threatening or require reoperation. Conversely, when FXI deficiency is diagnosed in advance and appropriate prophylactic treatment (FFP, tranexamic acid, etc.) is given, safe recovery without bleeding complications is possible in most surgeries. Therefore, diagnosed patients are recommended to always carry information on their coagulation status via a medic-alert card or a smartphone application, which is important for preventing treatment delays in emergencies.

Prognostic features in female patients

In women with FXI deficiency, menorrhagia and postpartum hemorrhage are important factors affecting prognosis. Untreated menorrhagia leads to iron deficiency anemia, reducing quality of life and sometimes requiring transfusion. However, menorrhagia can be effectively controlled with oral contraceptives, the levonorgestrel intrauterine system (hormonal intrauterine device), or tranexamic acid. For the risk of postpartum hemorrhage, the key is to establish an advance plan through multidisciplinary consultation with a hematologist and obstetrician before delivery and to have sufficient FFP and tranexamic acid prepared at the place of delivery. When such advance preparations are made, delivery outcomes in women with FXI deficiency are generally good.

Inhibitor development and long-term management issues

When an inhibitor develops in some patients who have received repeated FXI concentrate administration, subsequent FXI replacement therapy loses its effect, making bleeding management difficult. The incidence of inhibitors is low (estimated at about 5–10%), but once they develop, the effectiveness of immune tolerance induction is currently not as well established as in hemophilia A. In this case, recombinant FVIIa or aPCC is used as a bypassing agent, but the dose and effect are difficult to predict. In the long term, subcutaneously administrable RNA interference therapies and monoclonal antibodies targeting FXI are under development, so new treatment options may emerge in the future. There is also the expectation that advances in anti-FXI antibodies may paradoxically become a new breakthrough for resolving the problem of treatment resistance in FXI deficiency.


12. Prevention

Genetic counseling and family screening

Professional genetic counseling is recommended for patients with hereditary factor XI deficiency and individuals confirmed as carriers. Genetic counseling provides thorough information on the mode of inheritance of the disease (autosomal recessive), the probability of children being affected (25% when both parents are carriers), the clinical significance of heterozygous carrier status, and available genetic testing and prenatal diagnosis options. Preemptive screening of the patient's first-degree relatives—parents, siblings, children—through FXI:C measurement and, if necessary, F11 gene analysis is recommended. Individuals confirmed as carriers also need bleeding risk assessment before surgery and procedures, and if the spouse is from the same risk population (especially Ashkenazi Jews), the spouse's carrier status needs to be checked.

Advance planning before surgery and procedures

The most effective way to prevent bleeding complications in patients with hereditary factor XI deficiency is to always consult a hematologist in advance before any surgery or invasive procedure. Self-advocacy, in which patients actively inform non-hematologist physicians such as general practitioners, dentists, and obstetricians so that they recognize the FXI deficiency in advance and request hematology consultation, is important. In the preoperative evaluation, a treatment plan is established by comprehensively considering FXI:C measurement, review of bleeding history, the level of fibrinolytic activity at the procedure site, and the scale of surgery. For procedures at sites with high fibrinolytic activity (oral cavity, urinary tract, uterus), prophylactic tranexamic acid is recommended even for minor procedures. For high-risk surgery, FFP or FXI concentrate is administered in a planned manner before, during, and after surgery.

Preventive measures in daily life

Following a few preventive measures in daily life helps FXI deficiency patients minimize bleeding risk. First, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and antiplatelet agents inhibit platelet function and can further increase the bleeding risk of FXI deficiency patients, so whether to take them must be decided after consulting a physician. For analgesics for pain control, acetaminophen, which has no effect on platelets, is a safer choice. Second, in situations requiring anticoagulant therapy such as warfarin or direct oral anticoagulants (DOACs), the bleeding risk may be higher when FXI deficiency is present, so careful dose adjustment is needed. Third, always carry a medical alert card or medical alert bracelet so that medical staff can quickly identify the FXI deficiency in an emergency.

Pregnancy and delivery planning

When a woman with FXI deficiency is planning pregnancy or is pregnant, it is essential to register early with a multidisciplinary hematology–obstetrics team and establish a delivery plan. During pregnancy, FXI:C may rise slightly physiologically, but this rise alone does not completely eliminate the bleeding risk at delivery. The delivery plan includes preparing a reserve of FFP, a tranexamic acid administration plan, consideration of bleeding risk when choosing the mode of delivery (vaginal delivery or cesarean section), and review of whether epidural anesthesia can be used (risk of epidural hematoma). Because the bleeding risk may persist until 2–3 days postpartum, it is recommended to monitor FXI:C after delivery and use FFP and tranexamic acid prophylactically. Measuring FXI:C in the newborn within the first few weeks of life to determine early whether the child is affected should also be considered.


13. References

  1. Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med. 1953;82(1):171–174.
  2. Bolton-Maggs PHB, Patterson DA, Wensley RT, Tuddenham EGD. Definition of the bleeding tendency in factor XI-deficient kindreds—a clinical and laboratory study. Thromb Haemost. 1995;73(2):194–202.
  3. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med. 1991;325(3):153–158.
  4. Seligsohn U. Factor XI in haemostasis and thrombosis: past, present and future. Thromb Haemost. 2007;98(1):84–89.
  5. Zadra G, Asselta R, Tenchini ML, et al. Cloning and nucleotide sequence of the human factor XI cDNA. Nucleic Acids Res. 1991;19(13):3591.
  6. Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013;39(6):621–631.
  7. Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia. 2008;14(6):1183–1189.
  8. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European network of rare bleeding disorders. J Thromb Haemost. 2012;10(4):615–621.
  9. Salomon O, Steinberg DM, Dardik R, et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost. 2003;1(4):658–661.
  10. Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232–240.
  11. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342(10):696–701.
  12. Kamath S, Lip GY, Blann AD. Factor XI deficiency: management and treatment strategies. Br J Haematol. 2003;120(3):349–354.